Synvivo Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 10, 2027The maintenance fee for Systems and methods for reperfusion injury (US 11,782,051) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Multi-chambered cell culture device to model organ microphysiology (US 10,570,360) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 2 fees due Sep 15 to 22, 2027 · next Sep 15
- 1 fee due Nov 5, 2027The maintenance fee for Synthetic microfluidic systems for tumor metastasis (US 10,641,761) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,355,876 | Microfluidic assay for selection and optimization of drug delivery vehicles to tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,878,090 | Miniaturized electrothermal flow induced infusion pump In force · From the USPTO record | In force | From the USPTO record | |
| US 8,175,814 | Synthetic microfluidic microvasculature network In force · From the USPTO record | In force | From the USPTO record | |
| US 8,380,443 | Microfluidic assay for characterization of the leukocyte adhesion cascade In force · From the USPTO record | In force | From the USPTO record | |
| US 8,417,465 | Synthetic microfluidic blood-brain barrier In force · From the USPTO record | In force | From the USPTO record | |
| US 9,453,252 | Microfluidic assay in idealized microvascular network for selection and optimization of drug delivery vehicles to simulated tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 7,725,267 | Synthetic microfluidic microvasculature network In force · From the USPTO record | In force | From the USPTO record | |
| US 9,283,597 | Miniaturized electrothermal flow induced infusion pump In force · From the USPTO record | In force | From the USPTO record | |
| US 8,828,715 | Particle adhesion assay for microfluidic bifurcations In force · From the USPTO record | In force | From the USPTO record | |
| US 9,932,550 | Multi-chambered cell culture device to model organ microphysiology In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 18: 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded